TR201818978T4 - İnsanlardaki İnflamatuvar Rahatsızlıkların Tedavisine Yönelik Lipozomal Kortikosteroidler - Google Patents
İnsanlardaki İnflamatuvar Rahatsızlıkların Tedavisine Yönelik Lipozomal Kortikosteroidler Download PDFInfo
- Publication number
- TR201818978T4 TR201818978T4 TR2018/18978T TR201818978T TR201818978T4 TR 201818978 T4 TR201818978 T4 TR 201818978T4 TR 2018/18978 T TR2018/18978 T TR 2018/18978T TR 201818978 T TR201818978 T TR 201818978T TR 201818978 T4 TR201818978 T4 TR 201818978T4
- Authority
- TR
- Turkey
- Prior art keywords
- inflammatory
- humans
- disease
- corticosteroid
- treatment
- Prior art date
Links
- 239000003246 corticosteroid Substances 0.000 title abstract 4
- 229960001334 corticosteroids Drugs 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002757 inflammatory effect Effects 0.000 abstract 3
- 150000002632 lipids Chemical class 0.000 abstract 3
- 238000002560 therapeutic procedure Methods 0.000 abstract 3
- 230000001684 chronic effect Effects 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 230000004968 inflammatory condition Effects 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 abstract 2
- 229960005205 prednisolone Drugs 0.000 abstract 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 abstract 1
- 208000025747 Rheumatic disease Diseases 0.000 abstract 1
- 230000003110 anti-inflammatory effect Effects 0.000 abstract 1
- 230000037396 body weight Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 208000018631 connective tissue disease Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 239000002502 liposome Substances 0.000 abstract 1
- 238000012423 maintenance Methods 0.000 abstract 1
- 229960000485 methotrexate Drugs 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 230000003389 potentiating effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Buluş, yüksüz, vezikül oluşturan lipidlerden oluşan, isteğe bağlı olarak negatif yüklü vezikül oluşturan lipidlerin 10 mol yüzdesinden fazlasını ve/veya PEGile lipidlerin 10 mol yüzdesinden fazlasını içermeyen lipozomları içeren bir farmasötik bileşim ile ilgilidir, lipozomlar, 40-200 nm boyut aralığında seçilmiş bir ortalama partikül çapına sahiptir ve insanda iki haftada en fazla bir defa tedavi sıklığı ile en fazla 5 mg/kg vücut ağırlığı prednizolon dozu veya prednizolondan farklı olarak bir kortikosteroidin eşdeğer bir dozunda en az 2 hafta hızlı, kuvvetli ve dayanıklı bir anti-inflamatuvar etki sağlayarak, insanlardaki inflamatuvar rahatsızlıkların bölgeye özel tedavisine yönelik olarak suda çözünebilir formda bir birinci kortikosteroidi içerir. Ayrıca mevcut buluş, ikinci bir serbest kortikosteroid formülasyonu ile kronik tedavi ile kombinasyon halinde veya metotreksat gibi bir hastalığı modifiye edici ajan ile kronik tedavi ile kombinasyon halinde, romatizmal hastalık veya ilgili inflamatuvar bağ doku rahatsızlığı, inflamatuvar böbrek hastalıkları veya inflamatuvar bağırsak rahatsızlıkları gibi inflamatuvar rahatsızlıklarda idame tedavisi olarak verilen yukarıda geçen farmasötik bileşimin uygulanması ile ilgilidir.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| NLPCT/NL2011/050755 | 2011-11-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201818978T4 true TR201818978T4 (tr) | 2019-01-21 |
Family
ID=47215701
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/18978T TR201818978T4 (tr) | 2011-11-04 | 2012-11-02 | İnsanlardaki İnflamatuvar Rahatsızlıkların Tedavisine Yönelik Lipozomal Kortikosteroidler |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10471010B2 (tr) |
| EP (1) | EP2773325B1 (tr) |
| JP (2) | JP2014532697A (tr) |
| CN (1) | CN104144679A (tr) |
| AU (1) | AU2012331702B2 (tr) |
| CA (1) | CA2854430C (tr) |
| DK (1) | DK2773325T3 (tr) |
| ES (1) | ES2701748T3 (tr) |
| IN (1) | IN2014MN00887A (tr) |
| PL (1) | PL2773325T3 (tr) |
| PT (1) | PT2773325T (tr) |
| TR (1) | TR201818978T4 (tr) |
| WO (1) | WO2013066179A1 (tr) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20160101124A1 (en) * | 2014-10-13 | 2016-04-14 | King Abdullah International Medical Research Center | Nano-liposomal aminoglycoside-thymoquinone formulations |
| CN108289845A (zh) * | 2015-09-14 | 2018-07-17 | 维吉思康科技公司 | 皮下、舌下和口服治疗用空间稳定载体、用于治疗哺乳动物的组合物和方法 |
| EP3373910B1 (en) | 2015-11-10 | 2023-07-12 | Children's Research Institute, Children's National Medical Center | Echinomycin formulation, method of making and method of use thereof |
| SG11201805101RA (en) * | 2015-12-17 | 2018-07-30 | Univ Nanyang Tech | Nanoliposomes comprising corticosteroid as medicaments and methods to prepare them |
| CA3009119A1 (en) | 2015-12-28 | 2017-07-06 | Mb Biotech Ltd. | Liposomes for treatment of an autoimmune disease |
| JP2019515925A (ja) * | 2016-04-29 | 2019-06-13 | エンセラドゥス ファーマセウティカルス べー．フェー． | 炎症性病変又は領域に局所注射するためのリポソーム化コルチコステロイド |
| WO2018119413A1 (en) * | 2016-12-22 | 2018-06-28 | Lipidair, Llc | Targeted delivery methods and compositions for antihistamines |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4938949A (en) * | 1988-09-12 | 1990-07-03 | University Of New York | Treatment of damaged bone marrow and dosage units therefor |
| DE4341472A1 (de) * | 1993-12-02 | 1995-06-08 | Schering Ag | Verfahren zur Erhöhung der Stabilität von hydrophile Wirkstoffe enthaltenden Liposomensuspensionen |
| AU4424797A (en) * | 1996-09-18 | 1998-04-14 | Dragoco Inc. | Liposome encapsulated active agent dry powder composition |
| AU3169702A (en) * | 2000-12-07 | 2002-06-18 | Yamanouchi Europ Bv | Composition for treatment of inflammatory disorders |
| JP2005530719A (ja) * | 2002-03-29 | 2005-10-13 | ニューロジェン コーポレーション | 病原性炎症要素を有する状態の治療のための組み合わせ療法 |
| EP1371362A1 (en) | 2002-06-12 | 2003-12-17 | Universiteit Utrecht Holding B.V. | Composition for treatment of inflammatory disorders |
| DE10255106A1 (de) * | 2002-11-24 | 2004-06-09 | Novosom Ag | Liposomale Glucocorticoide |
| US20060115523A1 (en) | 2004-12-01 | 2006-06-01 | Konduri Kameswari S | Sterically stabilized liposome and triamcinolone composition for treating the respiratory tract of a mammal |
| WO2005072290A2 (en) * | 2004-01-23 | 2005-08-11 | Joslin Diabetes Center | Methods of treating, reducing, or preventing autoimmune conditions |
| WO2005092368A1 (en) * | 2004-03-26 | 2005-10-06 | Charite-Universität- Smedizin Berlin | Uses of galectin-2 |
| US8119156B2 (en) * | 2006-10-24 | 2012-02-21 | Aradigm Corporation | Dual action, inhaled formulations providing both an immediate and sustained release profile |
| HUE030134T2 (en) * | 2007-10-16 | 2017-04-28 | Zymogenetics Inc | Combination of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) and anti-CD20 agents for the treatment of autoimmune diseases |
| CN103417472B (zh) | 2008-05-14 | 2018-01-02 | 奥德纳米有限公司 | 用于治疗耳部病症的控制释放皮质类固醇组合物和方法 |
| EP2127639A1 (en) | 2008-05-26 | 2009-12-02 | Universiteit Utrecht Holding B.V. | Corticosteroid containing liposomes for treatment of cardiovascular diseases |
-
2012
- 2012-11-02 PL PL12788306T patent/PL2773325T3/pl unknown
- 2012-11-02 DK DK12788306.4T patent/DK2773325T3/en active
- 2012-11-02 EP EP12788306.4A patent/EP2773325B1/en active Active
- 2012-11-02 TR TR2018/18978T patent/TR201818978T4/tr unknown
- 2012-11-02 ES ES12788306T patent/ES2701748T3/es active Active
- 2012-11-02 PT PT12788306T patent/PT2773325T/pt unknown
- 2012-11-02 WO PCT/NL2012/050766 patent/WO2013066179A1/en active Application Filing
- 2012-11-02 CN CN201280065036.7A patent/CN104144679A/zh active Pending
- 2012-11-02 CA CA2854430A patent/CA2854430C/en active Active
- 2012-11-02 US US14/355,845 patent/US10471010B2/en active Active
- 2012-11-02 JP JP2014539900A patent/JP2014532697A/ja active Pending
- 2012-11-02 AU AU2012331702A patent/AU2012331702B2/en active Active
-
2014
- 2014-05-12 IN IN887MUN2014 patent/IN2014MN00887A/en unknown
-
2017
- 2017-07-06 JP JP2017132786A patent/JP6609286B2/ja active Active
-
2019
- 2019-11-11 US US16/680,283 patent/US20200253871A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2773325A1 (en) | 2014-09-10 |
| US20200253871A1 (en) | 2020-08-13 |
| AU2012331702B2 (en) | 2017-10-26 |
| ES2701748T3 (es) | 2019-02-25 |
| PL2773325T3 (pl) | 2019-03-29 |
| EP2773325B1 (en) | 2018-09-19 |
| IN2014MN00887A (tr) | 2015-04-17 |
| CN104144679A (zh) | 2014-11-12 |
| US20150050329A1 (en) | 2015-02-19 |
| US10471010B2 (en) | 2019-11-12 |
| AU2012331702A1 (en) | 2014-05-22 |
| NZ625022A (en) | 2016-06-24 |
| JP2014532697A (ja) | 2014-12-08 |
| DK2773325T3 (en) | 2019-01-14 |
| JP2017214401A (ja) | 2017-12-07 |
| CA2854430C (en) | 2021-06-01 |
| AU2012331702A2 (en) | 2014-05-22 |
| PT2773325T (pt) | 2018-12-19 |
| CA2854430A1 (en) | 2013-05-10 |
| JP6609286B2 (ja) | 2019-11-20 |
| WO2013066179A1 (en) | 2013-05-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201818978T4 (tr) | İnsanlardaki İnflamatuvar Rahatsızlıkların Tedavisine Yönelik Lipozomal Kortikosteroidler | |
| CY1120429T1 (el) | Παραγωγα κιναζολινης για τη θεραπευτικη αντιμετωπιση ιογενων λοιμωξεων και αλλων νοσων | |
| AU2018201997B2 (en) | Peptides which inhibit activated receptors and their use in cosmetic or pharmaceutical compositions | |
| Zeb et al. | Enhanced anti-rheumatic activity of methotrexate-entrapped ultradeformable liposomal gel in adjuvant-induced arthritis rat model | |
| JP2022058438A (ja) | 親油性抗炎症剤を含む脂質ナノ粒子およびその使用方法 | |
| AU2014205529B2 (en) | Methods and compositions for treatment of demyelinating diseases | |
| AR085120A1 (es) | Formulaciones de particulas en polvo seco que contienen dos o mas ingredientes activos para el tratamiento de las enfermedades obstructivas o inflamatorias de las vias respiratorias | |
| JP2013526545A5 (tr) | ||
| FI2854769T3 (fi) | Artriitin hoitomenetelmät | |
| JP2016529284A5 (tr) | ||
| JP2015523355A5 (tr) | ||
| JP2008512445A5 (tr) | ||
| JP2014532665A5 (tr) | ||
| AR091006A1 (es) | Formulaciones de testosterona proliposomal | |
| JP2015536952A (ja) | オリゴヌクレオチド癌療法の投薬および実施 | |
| BR112014015333A8 (pt) | composições lipossomais de clorito ou clorato | |
| JP2017503842A5 (tr) | ||
| EA201491479A1 (ru) | Производные лупановых тритерпеноидов и их фармацевтическое применение | |
| RU2020137384A (ru) | Средство для лечения опухоли и набор, содержащий липосомальную композицию гемцитабина | |
| BR112015022476A2 (pt) | composições de oxaliplatina de lipossoma para terapia de câncer | |
| US20240115730A1 (en) | Tissue-specific nucleic acid delivery by 1,2-dioleoyl-3-trimethylammonium-propane (dotap) lipid nanoparticles | |
| UA111147C2 (uk) | Способи та композиції для лікування або профілактики зовнішнього отиту | |
| CY1124635T1 (el) | Ξηρες φαρμακευτικες συνθεσεις που περιεχουν νανοσωματιδια ενεργου παραγοντα δεσμευμενα σε σωματιδια φορεα | |
| JP2016512247A5 (tr) | ||
| RU2013105783A (ru) | Парентеральные составы производных элацитарабина |